Alzheimer Therapeutics Market Growth Fueled by Research Momentum
Based on market forecasts, the alzheimer’s therapeutics sector will expand from USD 5.7 billion in 2025 to USD 13.13 billion by 2035, experiencing a CAGR of 8.7%. In 2024, North America led the market, while Asia-Pacific is set for the fastest growth ahead. Cholinesterase inhibitors dominated by product, but pipeline drugs are expected to grow the quickest. Hospital pharmacies held the top spot among end-users, with e-commerce projected for strong future growth.
Last Updated : 21 April 2026
Category: Therapeutic Area
Insight Code: 5130
Format: PDF / PPT / Excel